Now live: Pro — the full 13F research suite for serious investorsSee pricing →
JOHNSON & JOHNSON (JNJ)

Q1 2024 · 13F-HR

JOHNSON & JOHNSON (JNJ)holdings as filed

Filed 2024-05-10 · accession 0000904454-24-000285

$4.41B
Reported value
22
Positions
2024-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
49177J102KVUEKenvue Inc.$3.91B88.7%182,329,550CommonSHARED
36118A100Fusion Pharmaceuticals Inc.$78.3M1.77%3,670,516CommonSHARED
126638105CVRXCVRx, Inc.$74.7M1.69%4,103,430CommonSHARED
74366E102PTGXProtagonist Therapeutics Inc.$70.9M1.61%2,449,183CommonSHARED
82489T104SWAVUSDShockwave Medical, Inc.$54.3M1.23%166,812CommonSHARED
52490G102LEGNLegend Biotech Corporation$45.7M1.04%814,586CommonSHARED
G59665102MGTXMeiraGTx Holdings plc$40.3M0.91%6,641,064CommonSHARED
63009J107NBTXNanobiotix S.A.$36.6M0.83%5,623,816CommonSHARED
640979100NMRANeumora Therapeutics, Inc.$25.4M0.58%1,849,445CommonSHARED
31189P102FATEFate Therapeutics, Inc.$24.8M0.56%3,379,064CommonSHARED
74276L105PRCTProcept BioRobotics Corporation$17.7M0.40%357,939CommonSHARED
98401F105XNCRXencor, Inc.$16.6M0.38%748,062CommonSHARED
04280A100ARWRArrowhead Pharmaceuticals, Inc.$7.1M0.16%247,598CommonSHARED
929033108Vor Biopharma, Inc.$2.5M0.06%1,074,658CommonSHARED
M70700105NNOXNano-X Imaging Ltd.$1.6M0.04%158,852CommonSHARED
01438T106ALDXAldeyra Therapeutics, Inc.$979,9180.02%299,669CommonSHARED
09090D103BiomX Inc.$865,4400.02%1,923,201CommonSHARED
007002108TORCEURAdicet Bio, Inc.$856,5090.02%364,472CommonSHARED
34385P108LABStandard BioTools Inc$845,4310.02%311,967CommonSHARED
185063104CLSDUSDClearside Biomedical, Inc.$259,5320.01%169,629CommonSHARED
89237H209Tracon Pharmaceuticals, Inc.$36,1040.00%84,003CommonSHARED
81727U105SENS1GBPSenseonics Holdings, Inc.$29,0090.00%54,621CommonSHARED

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.